Health

World Affairs

US Politics

Tenax Therapeutics Shares Tumble 85% After Phase 3 Heart Drug Study Fails To Meet Primary Endpoint — Rttnews

←Back to story

Tenax Therapeutics Shares Tumble 85% After Phase 3 Heart Drug Study Fails To Meet Primary Endpoint

RttnewsView source article

Part of story

Tenax’s TNX-103 fails primary endpoint in Phase 3 PH-HFpEF trial

Tenax Therapeutics' stock collapsed on August 10, 2026, after the company announced its Phase 3 LEVEL trial of TNX-103 (oral levosimendan) failed to significantly improve walking distance in patients with pulmonary hypertension associated with heart failure compared to placebo, missing its primary endpoint.